JOHNSON, DONNA BURNETT
JOHNSON, DONNA BURNETT
DIPARTIMENTO DI ARCHITETTURA
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
2025 Grover, P; Lo, Sn; Li, I; Kuijpers, Amj; Kreidieh, F; Williamson, A; Amaral, T; Dimitriou, F; Placzke, J; Olino, K; Vitale, Mg; Saiag, P; Gutzmer, R; Allayous, C; Bagge, Ro; Mattsson, J; Asher, N; Carter, Tj; Meniawy, Tm; Lawless, Ar; Czapla, Ja; Warburton, L; Gaudy-Marquest, C; Grob, Jj; Collins, Rg; Zhang, E; Kessels, Ji; Neyns, B; Mehmi, I; Hamid, O; Julve, M; Furness, Ajs; Margolin, Ka; Levi-Ari, S; Ressler, Jm; Haque, W; Khattak, Ma; Wicky, A; Roberts-Thomson, R; Arance, A; Warrier, G; Schollenberger, Md; Parente, P; Chatziioannou, E; Lipson, Ej; Michielin, O; Weber, Js; Hoeller, C; Larkin, J; Atkins, Mb; Essner, R; Johnson, Db; Sullivan, Rj; Nathan, P; Schachter, J; Lebbe, C; Ascierto, Pa; Kluger, H; Rutkowski, P; Dummer, R; Garbe, C; Lorigan, Pc; Burton, E; Tawbi, Ha; Haanen, J; Carlino, Ms; Menzies, Am; Long, Gv
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
2025 Handel, Ee; Mckeown, J; Wei, J; Kankaria, Ra; Burnette, H; Johnson, Db; Lawless, A; Czapla, J; Sullivan, Rj; Albrecht, Lj; Zimmer, L; Mangana, J; Dummer, R; Kessels, Ji; Neyns, B; Allayous, C; Lebbe, C; Boatwright, C; Mehnert, Jm; Ottaviano, M; Ascierto, Pa; Czarnecka, Am; Rutkowski, P; Lo, Sn; Long, Gv; Menzies, Am; Carlino, Ms
Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors
2025 Dimitriou, F; Orloff, Mm; Koch Hein, Ec; Cheng, Pf; Hughes, If; Simeone, E; Montazeri, K; Grover, P; Mehmi, I; Gerard, Cl; Gaudy-Marqueste, C; Grob, Jj; Michielin, O; Hamid, O; Long, Gv; Sullivan, R; Kapiteijn, E; Johnson, Db; Ascierto, Pa; Joshua, Am; Carvajal, Rd; Butler, Mo; Hassel, Jc; Dummer, R
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
2024 Woodford, R; Mckeown, J; Hoeijmakers, Ll; Mangana, J; Dimitriou, F; Allayous, C; Zaman, F; Aya, F; Marsiglio, J; Goodman, R; Rayson, V; Placzke, J; Kessels, J; Ramalyte, E; Haque, W; Wilson, I; Trojaniello, C; Benannoune, N; Roberts-Thomson, R; Robert, C; Blank, Cu; Dummer, R; Lebbe, C; Haydon, A; Arance, A; Hu-Lieskovan, S; Johnson, Db; Mcarthur, Ga; Rutkowski, P; Neyns, B; Sullivan, Rj; Weber, J; Carlino, Ms; Ascierto, Pa; S, Lo; Long, Gv; Menzies, Am.
Use of artificial intelligence chatbots in clinical management of immune-related adverse events
2024 Burnette, H; Pabani, A; Von Itzstein, Ms; Switzer, B; Fan, R; Ye, F; Puzanov, I; Naidoo, J; Ascierto, Pa; Gerber, De; Ernstoff, Ms; Johnson, Db
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
2024 Jacques, Sk; Mckeown, J; Grover, P; Johnson, Db; Zaremba, A; Dimitriou, F; Weiser, R; Farid, M; Namikawa, K; Sullivan, Rj; Rutkowski, P; Lebbe, C; Hamid, O; Zager, Js; Michielin, O; Neyns, B; Nakamura, Y; Robert, C; Mehnert, J; Ascierto, Pa; Bhave, P; Park, B; Zimmer, L; Mangana, J; Mooradian, M; Placzke, J; Allayous, C; Glitza Oliva, Ic; Mehmi, I; Depalo, D; Wicky, A; Schwarze, Jk; Roy, S; Boatwright, C; Vanella, V; Long, Gv; Menzies, Am; Lo, Sn; Carlino, Ms
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
2024 Hepner, A; Versluis, Jm; Wallace, R; Allayous, C; Brown, Lj; Trojaniello, C; Gerard, Cl; Jansen, Yj; Bhave, P; Neyns, B; Haydon, A; Michielin, O; Mangana, J; Klein, O; Shoushtari, An; Warner, Ab; Ascierto, Pa; Mcquade, Jl; Carlino, Ms; Zimmer, L; Lebbe, C; Johnson, Db; Sandhu, S; Atkinson, V; Blank, Cu; Lo, Sn; Long, Gv; Menzies, Am
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge
2023 Ascierto, Pa; Avallone, A; Bifulco, C; Bracarda, S; Brody, Jd; Emens, La; Ferris, Rl; Formenti, Sc; Hamid, O; Johnson, Db; Kirchhoff, T; Klebanoff, Ca; Lesinski, Gb; Monette, A; Neyns, B; Odunsi, K; Paulos, Cm; Powell Dj, Jr; Rezvani, K; Segal, Bh; Singh, N; Sullivan, Rj; Fox, Ba; Puzanov, I
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma
2023 Goodman, Rs; Di Guardo, L; Maurichi, A; Kirwin, B; Khattak, A; Vanella, V; Lee, J; Lawless, A; Czapla, J; Spagnoletti, A; Ambrosini, M; Livingstone, E; Long, Gv; Sullivan, Rj; Carlino, Ms; Atkinson, V; Trojanello, C; Ascierto, Pa; Schadendorf, D; Warburton, L; Menzies, Am; Santinami, M; Johnson, Db
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
2023 Atkins, Mb; Ascierto, Pa; Feltquate, D; Gulley, Jl; Johnson, Db; Khushalani, Ni; Sosman, J; Yap, Ta; Kluger, H; Sullivan, Rj; Tawbi, H
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes
2023 Lee, J; Ahmed, T; Maurichi, A; Di Guardo, L; Stagno, Am; Warburton, L; Taylor, Am; Livingstone, E; Rehman, S; Khattak, A; Kahler, Kc; Vanella, V; Atkinson, V; Millward, M; Schadendorf, D; Johnson, Db; Ascierto, Pa; Hauschild, A; Lo, Sn; Long, Gv; Menzies, Am; Carlino, Ms.
Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data
2026 Flores, Tf; Tonorezos, Es; Bhatia, S; Brahmer, Jr; Cappelli, Lc; Cooper, M; Davies, M; Guild, S; Gunturu, K; Haanen, Jbag; Johnson, Db; Lacouture, Me; Leidner, R; Mitchell, S; Moledina, Dg; Moslehi, J; Naidoo, J; Obeid, M; Postow, M; Puzanov, I; Reid, Me; Santomasso, Bd; Schadendorf, D; Silk, Aw; Sullivan, Rj; Walunas, T; Wang, Y; Ascierto, Pa; Ernstoff, Ms
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma | 1.1 Articolo in rivista | 2025 | Grover, P; Lo, Sn; Li, I; Kuijpers, Amj; Kreidieh, F; Williamson, A; Amaral, T; Dimitriou, F; Placzke, J; Olino, K; Vitale, Mg; Saiag, P; Gutzmer, R; Allayous, C; Bagge, Ro; Mattsson, J; Asher, N; Carter, Tj; Meniawy, Tm; Lawless, Ar; Czapla, Ja; Warburton, L; Gaudy-Marquest, C; Grob, Jj; Collins, Rg; Zhang, E; Kessels, Ji; Neyns, B; Mehmi, I; Hamid, O; Julve, M; Furness, Ajs; Margolin, Ka; Levi-Ari, S; Ressler, Jm; Haque, W; Khattak, Ma; Wicky, A; Roberts-Thomson, R; Arance, A; Warrier, G; Schollenberger, Md; Parente, P; Chatziioannou, E; Lipson, Ej; Michielin, O; Weber, Js; Hoeller, C; Larkin, J; Atkins, Mb; Essner, R; Johnson, Db; Sullivan, Rj; Nathan, P; Schachter, J; Lebbe, C; Ascierto, Pa; Kluger, H; Rutkowski, P; Dummer, R; Garbe, C; Lorigan, Pc; Burton, E; Tawbi, Ha; Haanen, J; Carlino, Ms; Menzies, Am; Long, Gv | |
| Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma | 1.1 Articolo in rivista | 2025 | Handel, Ee; Mckeown, J; Wei, J; Kankaria, Ra; Burnette, H; Johnson, Db; Lawless, A; Czapla, J; Sullivan, Rj; Albrecht, Lj; Zimmer, L; Mangana, J; Dummer, R; Kessels, Ji; Neyns, B; Allayous, C; Lebbe, C; Boatwright, C; Mehnert, Jm; Ottaviano, M; Ascierto, Pa; Czarnecka, Am; Rutkowski, P; Lo, Sn; Long, Gv; Menzies, Am; Carlino, Ms | |
| Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors | 1.1 Articolo in rivista | 2025 | Dimitriou, F; Orloff, Mm; Koch Hein, Ec; Cheng, Pf; Hughes, If; Simeone, E; Montazeri, K; Grover, P; Mehmi, I; Gerard, Cl; Gaudy-Marqueste, C; Grob, Jj; Michielin, O; Hamid, O; Long, Gv; Sullivan, R; Kapiteijn, E; Johnson, Db; Ascierto, Pa; Joshua, Am; Carvajal, Rd; Butler, Mo; Hassel, Jc; Dummer, R | |
| Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy | 1.1 Articolo in rivista | 2024 | Woodford, R; Mckeown, J; Hoeijmakers, Ll; Mangana, J; Dimitriou, F; Allayous, C; Zaman, F; Aya, F; Marsiglio, J; Goodman, R; Rayson, V; Placzke, J; Kessels, J; Ramalyte, E; Haque, W; Wilson, I; Trojaniello, C; Benannoune, N; Roberts-Thomson, R; Robert, C; Blank, Cu; Dummer, R; Lebbe, C; Haydon, A; Arance, A; Hu-Lieskovan, S; Johnson, Db; Mcarthur, Ga; Rutkowski, P; Neyns, B; Sullivan, Rj; Weber, J; Carlino, Ms; Ascierto, Pa; S, Lo; Long, Gv; Menzies, Am. | |
| Use of artificial intelligence chatbots in clinical management of immune-related adverse events | 1.1 Articolo in rivista | 2024 | Burnette, H; Pabani, A; Von Itzstein, Ms; Switzer, B; Fan, R; Ye, F; Puzanov, I; Naidoo, J; Ascierto, Pa; Gerber, De; Ernstoff, Ms; Johnson, Db | |
| Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy | 1.1 Articolo in rivista | 2024 | Jacques, Sk; Mckeown, J; Grover, P; Johnson, Db; Zaremba, A; Dimitriou, F; Weiser, R; Farid, M; Namikawa, K; Sullivan, Rj; Rutkowski, P; Lebbe, C; Hamid, O; Zager, Js; Michielin, O; Neyns, B; Nakamura, Y; Robert, C; Mehnert, J; Ascierto, Pa; Bhave, P; Park, B; Zimmer, L; Mangana, J; Mooradian, M; Placzke, J; Allayous, C; Glitza Oliva, Ic; Mehmi, I; Depalo, D; Wicky, A; Schwarze, Jk; Roy, S; Boatwright, C; Vanella, V; Long, Gv; Menzies, Am; Lo, Sn; Carlino, Ms | |
| The features and management of acquired resistance to PD1-based therapy in metastatic melanoma | 1.1 Articolo in rivista | 2024 | Hepner, A; Versluis, Jm; Wallace, R; Allayous, C; Brown, Lj; Trojaniello, C; Gerard, Cl; Jansen, Yj; Bhave, P; Neyns, B; Haydon, A; Michielin, O; Mangana, J; Klein, O; Shoushtari, An; Warner, Ab; Ascierto, Pa; Mcquade, Jl; Carlino, Ms; Zimmer, L; Lebbe, C; Johnson, Db; Sandhu, S; Atkinson, V; Blank, Cu; Lo, Sn; Long, Gv; Menzies, Am | |
| Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge | 1.1 Articolo in rivista | 2023 | Ascierto, Pa; Avallone, A; Bifulco, C; Bracarda, S; Brody, Jd; Emens, La; Ferris, Rl; Formenti, Sc; Hamid, O; Johnson, Db; Kirchhoff, T; Klebanoff, Ca; Lesinski, Gb; Monette, A; Neyns, B; Odunsi, K; Paulos, Cm; Powell Dj, Jr; Rezvani, K; Segal, Bh; Singh, N; Sullivan, Rj; Fox, Ba; Puzanov, I | |
| Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma | 1.1 Articolo in rivista | 2023 | Goodman, Rs; Di Guardo, L; Maurichi, A; Kirwin, B; Khattak, A; Vanella, V; Lee, J; Lawless, A; Czapla, J; Spagnoletti, A; Ambrosini, M; Livingstone, E; Long, Gv; Sullivan, Rj; Carlino, Ms; Atkinson, V; Trojanello, C; Ascierto, Pa; Schadendorf, D; Warburton, L; Menzies, Am; Santinami, M; Johnson, Db | |
| Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies | 1.1 Articolo in rivista | 2023 | Atkins, Mb; Ascierto, Pa; Feltquate, D; Gulley, Jl; Johnson, Db; Khushalani, Ni; Sosman, J; Yap, Ta; Kluger, H; Sullivan, Rj; Tawbi, H | |
| BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes | 1.1 Articolo in rivista | 2023 | Lee, J; Ahmed, T; Maurichi, A; Di Guardo, L; Stagno, Am; Warburton, L; Taylor, Am; Livingstone, E; Rehman, S; Khattak, A; Kahler, Kc; Vanella, V; Atkinson, V; Millward, M; Schadendorf, D; Johnson, Db; Ascierto, Pa; Hauschild, A; Lo, Sn; Long, Gv; Menzies, Am; Carlino, Ms. | |
| Where is the data? Delayed and chronic irAE surveillance and management after cessation of ICIs: expert insights from SITC on survivorship care and the need for long-term data | 1.1 Articolo in rivista | 2026 | Flores, Tf; Tonorezos, Es; Bhatia, S; Brahmer, Jr; Cappelli, Lc; Cooper, M; Davies, M; Guild, S; Gunturu, K; Haanen, Jbag; Johnson, Db; Lacouture, Me; Leidner, R; Mitchell, S; Moledina, Dg; Moslehi, J; Naidoo, J; Obeid, M; Postow, M; Puzanov, I; Reid, Me; Santomasso, Bd; Schadendorf, D; Silk, Aw; Sullivan, Rj; Walunas, T; Wang, Y; Ascierto, Pa; Ernstoff, Ms |